Form Approved OMB No. 0920-1385 Exp. Date: 3/31/26

## Triazole-resistant Aspergillus fumigatus case report form Unique patient ID (DCIPHER): \_\_\_\_\_ ARLN specimen ID: \_\_\_\_\_ | ARLN isolate ID: \_\_\_\_\_ | ARLN patient ID: \_\_\_\_\_ Form completion data Name of person completing this form: Institution: \_\_\_ Email: Telephone: \_\_\_\_ Date form completed: Date of incident specimen collection (DISC)\*: \_\_\_\_\_\_\_ (mm-dd-yyyy) \*This is the earliest date that a patient had a positive test for triazole-resistant A. fumigatus A. Patient demographics 1. Age at DISC: (use months or days if patient \_\_ □ Years □ Months □ Days □ Unknown was aged <2 years) □ Male □ Female □ Unknown 2. Assigned sex at birth 3. Gender identity ☐ Male ☐ Female ☐ Transgender, non-binary, or another gender □ Prefer not to answer/Decline □ Unknown 4. What is your race and/or ☐ American Indian or Alaska Native ethnicity? (select all that apply Enter, for example, Navajo Nation, Blackfeet Tribe of the Blackfeet Indian Reservation of Montana, and enter additional details in Native Village of Barrow Inupiat Traditional Government, Nome Eskimo Community, Aztec, Maya, the spaces provided) ☐ Asian - provide details below □ Chinese □ Asian Indian □ Filipino □ Vietnamese □ Korean □ Japanese Enter, for example, Pakistani, Hmong, Afghan, etc. ☐ Black or African American – provide details below □ African American □ Jamaican □ Haitian □ Nigerian □ Ethiopian □ Somali Enter, for example, Trinidadian and Tobagonian, Ghanaian, Congolese, etc. ☐ Hispanic or Latino – provide details below □ Mexican □ Puerto Rican □ Salvadoran □ Cuban □ Dominican □ Guatemalan Enter, for example, Colombian, Honduran, Spaniard, etc. ☐ Middle Eastern or North African – provide details below □ Lebanese □ Iranian □ Egyptian □ Syrian □ Iraqi □ Israeli Enter, for example, Moroccan, Yemeni, Kurdish, etc.

CDC estimates the average public reporting burden for this collection of information as 30 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS H21-8, Atlanta, Georgia 30333; ATTN: PRA (0920-1385).

	□ Native Hawaiian or Pacific Islander – provide details below □ Native Hawaiian □ Samoan □ Chamorro □ Tongan □ Fijian □ Marshallese  Enter, for example, Chuukese, Palauan, Tahitian, etc. □ White – provide details below □ English □ German □ Irish □ Italian □ Polish □ Scottish  Enter, for example, French, Swedish, Norwegian, etc. □ White – provide details below
5. Patient's county of residence (Please do not write the word "County"; for example, write "Cook" instead of "Cook County"):	□ Unknown
6. Patient's state, jurisdiction, or territory of residence	□ Unknown
7. Patient's country of residence (e.g., USA)	□ Unknown
8. Healthcare facility name  (Note: 'healthcare facility' refers to the facility where the patient's incident specimen was collected)	□ Unknown
9. Healthcare facility CMS ID #	□ Unknown

A. Patient Demographics (continued)		
10. Healthcare facility ZIP code	□ Unknown	
11. Healthcare facility state, jurisdiction, or territory	□ Unknown	
12. Healthcare facility type	□ Acute care hospital (ACH) □ Long-term acute care hospital (LTACH) □ Skilled nursing facility with ventilated residents (vSNF) □ Skilled nursing facility without ventilated residents (SNF) □ Outpatient □ Unknown □ Other	

1. Cancer  Yes  No  Unknown  Hematologic malignancy specify type:  Solid organ malignancy specify type:  Chemotherapy If yes, specify:  No  Unknown If yes, choose one of the below		3. Chronic pulmonary diagnosis □ Yes □ No □ Unknown □ Chronic obstructive pulmonary disease (COPD) or emphysema □ Bronchiectasis □ Cystic fibrosis □ Allergic bronchopulmonary aspergillosis (ABPA) □ Pulmonary fibrosis □ Asthma □ Interstitial Lung Disease □ Other chronic pulmonary diagnosis			
Ever had CD4 < 200 cells/mm³ within past 6 ₪ Yes □ No □ Unknown	months	(specify):			
4. Positive respiratory viral test in 120 days befor Yes □ No □ Unknown	e or after DISC 🗆	5. Transplant received within 2 years before DISC  ☐ Yes ☐ No ☐ Unknown			
If yes, (select all that apply):  □ SARS-CoV-2 (PCR or antigen test)  □ antigen □ PCR □ unknown test type □ Influenza □ Other respiratory virus (specify)		□ Solid organ transplant: □ Lung □ Heart □ Kidney □ Pancreas □ Liver □ Skin graft □Other: □ Hematopoietic stem cell transplant (HSCT)			
6. Other selected conditions:   Cardiovascular disease (specify):  Diabetes mellitus End stage renal disease/dialysis Autoimmune disease(s) or inherited immu (specify): Medications/therapies that weaken the im TNF-alpha inhibitors (e.g., infliximab, etanercept) Other (specify):  Cirrhosis Liver disease without cirrhosis Systemic lupus erythematosus Active tuberculosis Pregnant Pregnant Contational are (weeks)	unodeficiency(-ies) nmune system adalimumab,	7. Other potentially relevant clinical information?  □ Yes (specify below) □ No □ Unknown			
Gestational age (weeks): □ Post-partum (gave birth within 6 weeks be					
C. Patient diagnosis and outcomes					
According to treating clinicians, which clinical syndrome(s) related to Aspergillus did the patient have?		nry aspergillosis (IPA) ndrome(s) related to A. fumigatus:			

C. Patient diagnosis and outcomes			
1. According to treating clinicians, which clinical syndrome(s) related to Aspergillus did	□ Invasive pulmonary aspergillosis (IPA)		
the patient have?	□ Other disease/syndrome(s) related to A. fumigatus:		
	□ Aspergillus was <b>not</b> believed to be causing clinical illness or is not mentioned in medical records		
	□ Unknown		
2. Was the patient hospitalized at an acute	□ Yes □ No □ Unknown		
care hospital in the 30 days before to 30 days after DISC?	If yes, dates of admission of hospitalization most proximal to DISC,		
	Admission date: (mm-dd-yyyy)		

	Discharge date: (mm-dd-yyyy) □ Still hospitalized
	If yes,
	Received ICU-level care in the 14 days <i>before</i> DISC?: ☐ Yes ☐ No ☐ Unknown
	Received ICU-level care in the 14 days after DISC?:   Yes   No   Unknown
	Discharge ICD-10 diagnosis code(s):
3. Died within 30 days after DISC?	□ No
	□ Yes, date of death (mm-dd-yyyy) Cause(s) of death
	□ Unknown

D. Antifu	ngal treatment: Did the patient recei	ve antifungal drugs during the 60 da	ays before to 30 days after the	DISC?   Yes   No
Unknowr	ı		<u> </u>	
	lease complete the table below for ea			
	e of the following to complete each roricin B lipid complex (ABLC)		savuconazole (ISA) Oth	er drug (specify):
	Al Amphotericin B (L-AmB)		raconazole (ITC)	ici didg (Specify).
	ricin B colloidal dispersion (ABCD)		Aicafungin (MFG)	
Anidulafu	ıngin (ANF)			known drug (UNK)
_		Ibrexafungerp (IBR) V	oriconazole (VRC)	
Drug Abbrev	b. First date given (mm-dd-yyyy)	c. Last date given (mm-dd-yyyy)	d. Indication	e. Therapeutic drug monitoring (TDM)
			□ Prophylaxis □ Treatment for Aspergillus □ Treatment for non-	☐ Yes Date of earliest TDM: TDM level:  Date of second TDM:
		□ Stop date unknown	Aspergillus infection	TDM level:
				□ No
	□ Start date unknown □ Start date was >60 days before		☐ Prophylaxis☐ Treatment for Aspergillus	□ Yes Date of earliest TDM: TDM level:
	DISC	completed □ Stop date unknown	☐ Treatment for non- Aspergillus infection	Date of second TDM: TDM level:
				□ No
	□ Start date unknown		□ Prophylaxis □ Treatment for Aspergillus	□ Yes Date of earliest TDM: TDM level:
	□ Start date was >60 days before DISC	□ Still on treatment at time CRF completed □ Stop date unknown	☐ Treatment for non- Aspergillus infection	Date of second TDM: TDM level:
				□ No
	☐ Start date unknown☐ Start date was >60 days before	☐ Still on treatment at time CRF	□ Prophylaxis □ Treatment for Aspergillus □ Treatment for non-	☐ Yes Date of earliest TDM: TDM level:
	DISC	completed □ Stop date unknown	Aspergillus infection	Date of second TDM:  TDM level:  □ No
	☐ Start date unknown	— — — — — — — — — — — — — — — — — — —	□ Prophylaxis □ Treatment for Aspergillus	☐ Yes Date of earliest TDM: TDM level:
	□ Start date was >60 days before DISC	□ Still on treatment at time CRF completed □ Stop date unknown	□ Treatment for non- Aspergillus infection	Date of second TDM: TDM level:
				□ No

Note that "you" in these question  1. Person interviewed	☐ Patient ☐ Someone other than the p	patient, (specify rela	tionship	to patient):
	·	,,,,	•	,
2. What was your job or				
occupation before [DISC]?	□ Unemployed □ Student □ Retired □ N/A □ Refused to answer □ Unknown			
3. What was your industry	□ Unemployed □ Student □ Retired □ N/A			
before [DISC]?	□ Refused to answer □ Unknown			
3. Did you travel outside of [healthcare facility state] within 3 months before [DISC]? (note: if healthcare facility is in a different state from patient's residence, then please count time spent in the patient's home state as "travel")	□ Yes □ No □ Unknown			
List state(s), territory(-ies), iurisdiction(s), country(-ies)				
4. Did you perform any of the	Gardening	□ Yes	□ No	□ Unknown
following activities during the	Handling compost	□ Yes		□ Unknown
90 days before [DISC]	Handling a fungicide product (agricultu Handling a fungicide product (home ga		□ No	□ Unknown
	Spending time on a farm	□ Yes	□ No	□ Unknown
	If patient spent time on a farm in 90 da applicable), and activities performed o	n farm:		
dditional comments:				